Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.
Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.
抑制 C-X-C 趋化因子受体 2 (CXCR2) 介导的中性粒细胞募集作为 Kirsten 大鼠肉瘤病毒癌基因同源物 (KRAS) 突变肺腺癌的靶向治疗。
批准号：
428770
负责人：
De Meo Meghan
金额：
$1.27万
依托单位：
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-12-01 至 2020-12-01
中文摘要
翻译
“肺癌是最致命的癌症。超过50%的患者在癌症已经扩散到其他器官时才被诊断出来。由于肿瘤细胞与正常细胞的差异，很难开发出专门识别肿瘤细胞的药物
英文摘要
"Lung cancer is the deadliest cancer. More than 50% of patients are diagnosed when their cancer has already spread to other organs. It is hard to develop drugs that specifically recognize tumour cells since the differences between tumour and normal cells
期刊论文(0)
专著(0)
科研奖励(0)
会议论文